TY - JOUR
T1 - Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden
AU - Cole, Stephen R.
AU - Napravnik, Sonia
AU - Mugavero, Michael J.
AU - Lau, Bryan
AU - Eron, Joseph
AU - Saag, Michael S.
PY - 2010/1
Y1 - 2010/1
N2 - Plasma human immunodeficiency virus type 1 (HIV-1) viral load is a valuable tool for HIV research and clinical care but is often used in a noncumulative manner. The authors developed copy-years viremia as a measure of cumulative plasma HIV-1 viral load exposure among 297 HIV seroconverters from the Multicenter AIDS Cohort Study (1984-1996). Men were followed from seroconversion to incident acquired immunodeficiency syndrome (AIDS), death, or the beginning of the combination antiretroviral therapy era (January 1, 1996); the median duration of follow-up was 4.6 years (interquartile range (IQR), 2.7-6.5). The median viral load and level of copy-years viremia over 2,281 semiannual follow-up assessments were 29,628 copies/mL (IQR, 8,547-80,210) and 63,659 copies × years/mL (IQR, 15,935-180,341). A total of 127 men developed AIDS or died, and 170 survived AIDSfree and were censored on January 1, 1996, or lost to follow-up. Rank correlations between copy-years viremia and other measures of viral load were 0.56-0.87. Each log10 increase in copy-years viremia was associated with a 1.70-fold increased hazard (95% confidence interval: 0.94, 3.07) of AIDS or death, independently of infection duration, age, race, CD4 cell count, set-point, peak viral load, or most recent viral load. Copy-years viremia, a novel measure of cumulative viral burden, may provide prognostic information beyond traditional single measures of viremia.
AB - Plasma human immunodeficiency virus type 1 (HIV-1) viral load is a valuable tool for HIV research and clinical care but is often used in a noncumulative manner. The authors developed copy-years viremia as a measure of cumulative plasma HIV-1 viral load exposure among 297 HIV seroconverters from the Multicenter AIDS Cohort Study (1984-1996). Men were followed from seroconversion to incident acquired immunodeficiency syndrome (AIDS), death, or the beginning of the combination antiretroviral therapy era (January 1, 1996); the median duration of follow-up was 4.6 years (interquartile range (IQR), 2.7-6.5). The median viral load and level of copy-years viremia over 2,281 semiannual follow-up assessments were 29,628 copies/mL (IQR, 8,547-80,210) and 63,659 copies × years/mL (IQR, 15,935-180,341). A total of 127 men developed AIDS or died, and 170 survived AIDSfree and were censored on January 1, 1996, or lost to follow-up. Rank correlations between copy-years viremia and other measures of viral load were 0.56-0.87. Each log10 increase in copy-years viremia was associated with a 1.70-fold increased hazard (95% confidence interval: 0.94, 3.07) of AIDS or death, independently of infection duration, age, race, CD4 cell count, set-point, peak viral load, or most recent viral load. Copy-years viremia, a novel measure of cumulative viral burden, may provide prognostic information beyond traditional single measures of viremia.
KW - Acquired immunodeficiency syndrome
KW - HIV
KW - HIV infections
KW - Viral load
KW - Viremia
UR - http://www.scopus.com/inward/record.url?scp=73949092992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73949092992&partnerID=8YFLogxK
U2 - 10.1093/aje/kwp347
DO - 10.1093/aje/kwp347
M3 - Article
C2 - 20007202
AN - SCOPUS:73949092992
SN - 0002-9262
VL - 171
SP - 198
EP - 205
JO - American Journal of Epidemiology
JF - American Journal of Epidemiology
IS - 2
ER -